TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT06263231: A Study to Investigate Efficacy & Safety of Intratumoral INT230-6 Compared to US Standard of Care in Adults With Soft Tissue Sarcomas (INVINCIBLE-3)

Sponsor: Intensity Therapeutics, Inc. · Phase: PHASE3 · Area: ONCOLOGY · Target Enrollment: 333 pts

Competing Trials Overlap

11 Active Trials

Excess Burn Exposure

$11,939,928

Rescue Site Savings

+$7,872,480

Unlock Full NCT06263231 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06263231 Rescue Dossier →